Fate Therapeutics (FATE) Tops Q2 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $940 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
• Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate